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Background: Circulating endothelial progenitor cells (EPCs) capture technology improves endothelialization rates of
sirolimus-eluting stents (SES), but the problem of delayed re-endothelialization, as well as endothelial dysfunction,
has still not been overcome. Therefore, we investigated whether the combination coating of hyaluronan-chitosan
(HC) and anti-CD34 antibody applied on an SES (HCASES) can promote endothelialization, while reducing
neointimal formation and inflammation.
Methods: Sirolimus-eluting stents(SES), anti-CD34 antibody stents (GS) and HC-anti-CD34 antibody combined with
sirolimus-eluting stents (HCASES) were deployed in 54 normal porcine arteries and harvested for scanning electron
microscopy (SEM) and histological analysis. The ratio of endothelial coverage above the stents was evaluated by
SEM analysis at 7, 14 and 28 days. The percentage of in-stent stenosis was histologically analyzed at 14 and 28 days.
Results: SEM analysis at 7 days showed that endothelial strut coverage was increased in the HCASES group
(68±7%) compared with that in the SES group (31±4%, p=0.02). At 14 days, stent surface endothelialization,
evaluated by SEM, showed a significantly higher extent of endothelial coverage above struts in the GS (95 ± 2%)
and the HCASES groups (87±4%) compared with that in the SES group (51±6%, p=0.02). Histological examination
showed that the percentage of stenosis in the HCASES group was not significantly different to that of the SES and
GS groups (both p> 0.05). At 28 days, there was no difference in the rates of endothelial coverage between the
HCASES and GS groups. The HCASES group showed less stenosis than that in the GS group (P < 0.05), but it was
not significantly different from the SES group (P=0.068).
Conclusions: SEM and histology demonstrated that HCASESs can promote re-endothelialization while enhancing
antiproliferative effects.
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The widespread use of drug-eluting stents, allowing
programmable localized elution of drugs to inhibit
neointimal formation, has considerably reduced the inci-
dence of in-stent restenosis compared with bare metal
stents [1-3]. However, the beneficial effect of drug elu-
tion is overshadowed by late in-stent thrombosis (LST),
caused by delayed re-endothelialization as well as local
hypersensitivity reactions potentially related to the drug,
the polymer, or both, and this is a potentially fatal com-
plication [4-6]. There is accumulating evidence that res-
toration of a newly established and functional
endothelium is a prerequisite for the effective inhibition
of neointimal hyperplasia and stent thrombosis in the
vascular repair response [7,8].
The capture of circulating endothelial progenitor cells
(EPCs) to an anti-CD34 antibody stent(GS) surface,
using an immobilized antihuman CD34 antibody, has been
proposed to contribute to accelerate re-endothelialization
and decrease thrombogenicity [9]. Moreover, the combin-
ation of EPC-capture and drug-elution technology, such
as sirolimus-eluting stents (SES) with immobilized GS
(SES–anti-CD34 stent), has been shown to enhance the
degree of endothelial cell coverage compared with an SES
alone [10]. While EPCs improve the percentage of stent
strut endothelialization of SESs, endothelial dysfunction is
still present, and its long-term consequences remain to be
determined, as demonstrated by the occurrence of LST,
even with GS [11].
Recently, a novel coating with a “prohealing” approach,
hyaluronan -chitosan (HC) multilayer coating, was dis-
covered, which can promote the adhesion, proliferation
and differentiation of EPCs. This coating has good bio-
compatibility as well as anticoagulant activity, which
may contribute to the restoration of functional endothe-
lium [12]. In the current study, we tested the hypothesis
that HC-anti-CD34 antibody combined with sirolimus-Figure 1 After implanting CD34 coated stents in swine vessel, EPCs in
CD34 monoclonal antibody on the stent surface,differentiated into va
48 hours later,about 85% of stent surface was covered with monolayer vaseluting stents (HCASES) enhance the degree of endothe-
lial cell coverage compared with SESs alone.
Methods
Devices used in the study
The current study used the anti-CD34 antibody stent
(GS), the sirolimus-eluting stent (SES), and the
HCASES. The control stents included the GS and SES.
They are commercially available stents (SES; Cypher,
Cordis, Miami, FL, USA, and GS; Genous, OrbusNeich
Medical, Fort Lauderdale, FL, USA). Electrostatic self-
assembly multilayer-coating endovascular stents loaded
with CD34 antibody were prepared (patent WO2009/
04955A1). Observing the surface of basis coating by
atomic mechanics microscope,there was uniformly dense
island arrangement. The bioactive matrix coatings effect-
ively improved hemocompatibility of the metal stent sur-
face by platelet adhesion experiment by scanning
electron microscopy. The feasibility of accelerate
endothelialization was evaluated by scanning electron
microscopy and immunofluorescence (Figure 1). The
antibody stents can capture EPCs rapidly in fresh human
peripheral blood in vitro. The amount of CD34 antibody
loaded per 316 L stainless steel coronary artery stent
was 50 ± 18 ng and 8.5± 1.5 μg of sirolimus was loaded
for the HCASES. HCASESs were immersed into fresh
blood with heparin, incubated at 37°C for 1 h, washed
with Tween 80-PBS. The biological activity of the anti-
body was unchanged after the HCASES was stored at
4°C for half a year.Experimental design
The study protocol was approved by the Animal Care
and Use Committee of the China Medical University.
The present study was performed in accordance with
the Guide for the Care and Use of Laboratory Animalsthe peripheral blood can be quickly and specificity captured by
scular endothelial cells by fluorescence immunohistochemistry.
cular endothelial cells by SEM.
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revised 1996).
In our study, investigators were blinded to the type of
stent, which was randomized and deployed in normal
coronary arteries in 27 swine (54 coronary arteries) and
harvested at 7, 14 and 28 days. Nine swine were sacri-
ficed at each time point (18 stents: six SESs;six Gs;six
HCASESs), and they were investigated for endotheliali-
zation using SEM and assessed for neointimal prolifera-
tion by histomorphometry.Interventional procedure
All animals were pre-treated with a daily dose of 325 mg
acetylsalicylic acid and 75 mg clopidogrel for 3 days
prior to surgery and on each subsequent day until death.
Twenty- seven domestic juvenile pigs, 30–35 kg in
weight, were implanted with an SES, GS or HCASES in
the left anterior descending and left coronary artery or
right coronary artery. Sedation was achieved with intra-
muscular injection of ketamine (25 mg/kg body weight),
xylazine (3 mg/kg body weight), and acepromazine (0.2
mg). Surgical access was obtained by cutting down on
the left femoral artery. An intravenous bolus of 5000 IU
of heparin was administered to achieve an activated clot-
ting time of 250 to 300 s during the procedure. Before
placing catheters to perform baseline angiograms, nitro-
glycerin was administered intra-arterially to relieve vaso-
spasm. According to angiographic analysis of the vessel
size, the appropriate stent was delivered to the intended
site via fluoroscopic guidance, and stent implantation
was performed (stent-to-artery ratio of 1.1:1.0). Angio-
grams were performed immediately. After deployment,
the catheters and introducer sheath were removed, the
surgical incision was repaired, and the skin was closed in
two layers. Animals were euthanized (at the designated
time) by an intravenous injection of a lethal dose of so-
dium pentobarbital.Histological analysis
Hearts were excised and the stented segments, as well as
adjacent vessels (>5 mm of the native vessel on both
sides of the stent), were dissected from the heart. The
treated arteries were pressure-perfused with 500 ml of
0.9% saline to wash away blood cells, and then they
underwent perfusion fixation for 30 min at 100 mm Hg
pressure with formaldehyde buffered in PBS (pH 7.4).
The dissected vessel was cut transversely into two equal
parts. The first segment was fixed in 2% glutaraldehyde
for SEM, and the remainder was stored in 10% neutral
buffered-formalin overnight for histological analysis. The
arteries for histological sections were processed for
epoxy embedding [13,14].SEM analysis
Arterial segments for SEM were sheared longitudinally
to unmask the lumen surface and then dehydrated in a
graded ethanol series. After critical point drying in car-
bon dioxide, the samples were mounted on specific stubs
and sputter-coated with gold. The tissue specimens were
observed using a JEOL JSM-T300 SEM (Tokyo, Japan).
To present the entire appearance, low power photo-
graphs of 15×, 35× and 50× were taken of the luminal
stent surface. Regions of interest were photographed at
further magnifications of 200× and 500× for direct
visualization of endothelial cells (ECs). The degree of
endothelialization above and between stent struts was
surveyed via morphometry software (Image-Pro Plus 6.0,
Media Cybernetics, USA), and then reported as the per-
centage of endothelial coverage.
Histomorphometric and histopathological evaluation
For histology, the dissected arterial segments were gently
flushed with PBS for 30 s and placed in a 10% formalin/
PBS solution for further processing. The sections were
stained with hematoxylin & eosin (HE). Injury and in-
flammatory scores were assessed by a blinded patholo-
gist according to the published methods of Schwartz
(0–3) and Kornowski (0–3), respectively [13]. In addition,
the cross-sectional areas (including external elastic lam-
ina, internal elastic lamina and lumen) of each section
were measured with digital morphometry. Areas of the
stent and lumen were measured and the percentage of
stenosis was calculated ([stent area - lumen area]/stent
area ×100%). Neointimal thickness was defined as the
distance from the inner surface of each stent strut to the
luminal border.
Statistical analysis
Continuous data are expressed as mean ± standard devi-
ation. All data were analyzed using SPSS software (SPSS
13.0; SPSS, Chicago, IL). A comparison of continuous
variables between groups (including luminal areas,
neointimal areas, and neointimal thicknesses) was per-
formed using one-way ANOVA analysis.
For endothelialization rates, statistical comparisons
were performed using the Wilcoxon test for two groups
or the Kruskal-Wallis test for three or more groups. A
p value of ≤0.05 was considered statistically significant.
Results
Evaluation of stent endothelialization by SEM
A total of 18 stents, including six GSs, six SESs, and six
HCASESs, were harvested at each time point. The ratio
of endothelial coverage above the stents was evaluated
by SEM at each time point. SEM analysis at 7 days
showed the greatest endothelialization rates in the GS
group (83±5%), and there was also a significant increase
Table 1 Quantitative Scanning Electron Microscopy:
Percentage Endothelium Covering The Stent Struts at 7
Days, 14 Days and 28 Days
Endothelialization (SEM) GS SES HCASES P value
7 days (n=9 each)
Above struts 83±5%§ 31±4%* 68±7%§* 0.027
Between 90±2% 74±8%* 85±5%* 0.044
14 days (n=9 each)
Above struts 95±2% 51±6% 87±4% 0.022
Between 98±2% 89±4%* 95±3%* 0.031
28 days (n=9 each)
Above struts 97±3% 74±8%* 95±4%* 0.042
Between 100±0% 94±2% 100±0% 0.079
§P<0.05 for GS vs HCASES.
¶P<0.05 for GS vs SES.
*P<0.05 for SES vs HCASES.
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±7%) compared with the SES group (31±4%; p=0.02;
Table 1). High-magnification SEM images (200× and
500×) showed that GSs and HCASESs were closely cov-
ered with cells with an endothelial-like phenotype,
while this was not the case with SESs. At 14 days, stent
surface endothelialization evaluated by SEM showed aFigure 2 Representative SEM images of the three types of stents at 1
showed the greatest endothelialization rates in the GS group ( GS-7days ),
in the HCASES group ( HCASES-7 days) compared with the SES group (SES
endothelial coverage on the stent struts of the three different types , and r
500× for direct visualization of ECs.significantly higher extent of endothelial coverage above
struts in the GS (95 ± 2%) and HCASES groups (87±4%)
compared with that in the SES group (51±6%; p=0.02;
Table 1). Low-magnification SEM images (15×, 35×, and
50×) showed thin endothelial coverage on the stent
struts of the three different types (Figures 2, 3). How-
ever, high-magnification SEM images ( 200× and 500×)
showed that endothelial strut coverage on SESs was
partial and discontinuous (Figure 2). Stent surface endo-
thelial coverage was nearly complete in the HCASES
group (95±4%), similar to that in the GS group
(97±3%) at 28 days, whereas the SES group (74±8%)
showed the lowest endothelialization rates (Table 1).
There was no difference in the rate of endothelial cover-
age between the HCASES and GS groups. Furthermore,
high-magnification SEM showed that endothelial cells
exhibited a cobblestone-like phenotype, indicative of a
mature functional endothelium in the HCASES and
GS groups.
Evaluation of stent efficacy by histology
At the 2-week follow-up, histological examination
showed that the injury and inflammation scores were
not significantly different between the three groups
(p =0.436 and 0.482, respectively) because the stents-week and 2-week follow-ups. SEM (magnification×200) at 7 days
and there was also a significant increase in endothelial strut coverage
-7 days). At 14 days, Low-magnification SEM images (50×) showed thin
egions of interest were photographed at further magnifications of
Figure 3 Representative lower-power SEM images of 15× and 35× for the whole face of the HCASES at 14 days.
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1.1:1.0. Similarly, the percentage of stenosis of the
HCASES group was not different from that of the SES
and GS groups (both p > 0.05) (Table 2). At 28 days, the
SES group had the least amount of neointimal thickness
compared with the other groups. However, the HCASES
group showed less stenosis than that in the GS group
(p < 0.05), but there was no significant difference com-
pared with the SES group (p=0.068). In addition, there
was less inflammation in the HCASES and SES groups
compared with that in the GS group (Table 2). Figure 4
shows representative images of histomorphometry for
each stent type. SEM and histological analyses demon-
strated that HCASESs promoted enhanced endotheliali-
zation, when it reducd neointimal formation and
inflammation at 28 days.Table 2 Histomorphometric and Histopathologic Finding at 1






Lumen area (mm2) 2.76±0.43
Intimal area(mm2) 1.82±0.94
Neointimal thickness(μm) 145.39±72.57
Percent of stenosis (%) 17.88±8.24
28 days(n=9 each)
IEL area(mm2) 4.76±0.84
Lumen area (mm2) 1.96±0.47§
Intimal area(mm2) 2.80±0.37§
Neointimal thickness(μm) 276.25±108.36§
Percent of stenosis (%) 33.74±11.85§
Injury score 0.81±0.14
Inflammation score 1.69±0.33§
Data are mean±SD. IEL, internal elastic lamina.
*P<0.05 for SES vs HCASES.
§P<0.05 for GS vs HCASES.
¶P<0.05 for GS vs SES.
GS = anti-CD34 antibody stent; SES= sirolimus-eluting stent.
HCASES = HC-anti-CD34 antibody combined with a sirolimus-eluting stent.Discussion
Despite the fact that the SES has greatly reduced the in-
cidence of in-stent restenosis compared with bare metal
stents, delayed re-endothelialization may increase the
risk of late-stent thrombosis and high lethality [6,11]. It
is imperative to hasten the healing of injured endothe-
lium after stent implantation. In the current study,
delayed re-endothelialization in SESs was ameliorated by
a novel combination of coating of HC-anti-CD34 anti-
body, which was added to a cardiovascular device to ac-
celerate endothelialization. A coating of anti-CD34
antibody has been reported to cause rapid re-
endothelialization by the attraction and adhesion of cir-
culating EPCs and has proven to be feasible and safe by
recent studies [15,16]. Furthermore, HC has been shown
to be non-toxic and non-anaphylactic, with an excellent4 Days and 28 Days Following Implantation of GS, SES, or















Figure 4 Representative low-power photomicrographs (magnification×4) and high-power photomicrographs (magnification ×10) at 28
days after implantation of GS, SES and HCASES in porcine coronary arteries. The HCASES group showed less stenosis than that in the GS
group,and there was no significant difference compared with the SES group . Of note , stent struts( shown in GS1 and SES1) may be deformed
by excessive strength when the dissected vessel is cut transversely into two equal parts.
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the establishment of healthy, functional ECs [12,17]. In
our study, both histological and SEM examination
demonstrated that the coverage rate of stent struts in
HCASESs (Above struts: 87±4%, Between struts: 95±3%,
14 days) was to be well matched with that in the
SES–anti-CD34 stent (Above struts: 82±8%, Between
struts: 96±2%, 14 days) as previously reported [10].
These results indicated that the combination of a coating
of HC-anti-CD34 antibody applied on SESs is more suit-
able for the enhanced adhesion of EPCs and growth of
ECs than EPCs captured on SESs alone. Min Yin et al.
reported a combination of coating with mussel adhesive
polypeptide and anti-CD34 antibody on the surface of vas-
cular stents, which can significantly enhance the attach-
ment of EPCs as well as ECs, and greatly reduce platelet
adhesion, indicative of better blood compatibility [18].
Recently, an increasing amount of researchers have
investigated endothelial function and maturity (CD31
expression) [4,5,19]. Nakazawa et al. used confocal mi-
croscopy to assess the presence of mature ECs by the
detection of CD31/PECAM-1- positive cells [10]. How-
ever, accumulating data have shown that there is a dis-
parity between endothelialization rates by SEM and
PECAM-1 positive rates by confocal microscopy ana-
lysis [10,20]. We consider that this disparity may resultfrom dysfunctional ECs without PECAM-1 expression.
Endothelial dysfunction may be related to the nonselec-
tive effect of inhibition of sirolimus on ECs and
EPCs. Furthermore, in vitro cell culture studies have
demonstrated that the antiproliferative concentration
(−log IC50:5.23 ±0.08) in smooth muscle cells is similar
in ECs (4.80 ±0.05) and EPCs (5.14 ±0.03) [10,21,22]. In
the current study, HC coating promoted the adhesion
of EPCs and the growth of ECs, and then the synergistic
effect of HC-anti-CD34 antibody coating offset the in-
hibitory effect of sirolimus on ECs as well as EPCs.
However, a large percentage of endothelial coverage by
SEM does not equate to healthy endothelial cells.
Healthy and mature ECs may express eNOS, vWF, and
CD31/PECAM-1 [10,23]. Although we could not assess
the maturation of the endothelium or ECs (eNOS, vWF
or CD31/PECAM-1 expression) via immunocytochem-
istry or confocal microscopy, the rate of endothelializa-
tion was increased by 45% by 28 days in the HCASES,
which was similar to that in the GS (up to 97±3%).
Therefore, the combination coating of HC-anti-CD34
antibody enhanced stent endothelialization by offsetting
the inhibitory effects of sirolimus on ECs and EPCs
when applied on SESs. The major challenge in the
present study was to confer the potential benefit of HC-
anti-CD34 coating to a stent system in vivo.
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protective effect of HCASESs on neointimal hyperplasia.
Histopathological evaluation confirmed that HCASESs
displayed a lower amount of neointimal hyperplasia and
less inflammatory reaction compared with GSs, while
maintaining EPC recruiting potential via HC-anti-CD34
coating. These results are consistent with the notion that
sirolimus is characterized by immunosuppressive and
anti-inflammatory effects [18,24-26]. Nevertheless, it has
been reported that SESs might lead to the formation of
atherosclerotic and thrombogenic neointima in the
stent-implanted site [27,28]. This phenomenon may be
concerned with endothelial dysfunction after SES im-
plantation. Moreover, there has been considerable debate
on the long-term safety and efficacy of SES, given the
potential for late stent thrombosis, as well as possibly
late catch-up in restenosis. In a sense, we think SES
might be considered obsolete because of its potential
risk of late stent thrombosis. Accordingly, further studies
are required to determine the potential mechanisms of
in-stent restenosis and vascular healing in the condition
of atherosclerosis.Conclusion
Our findings indicate that the combination coating of
HC- anti-CD34 antibody applied on a SES (HCASES)
can promote endothelialization, while reducing neointi-
mal formation and inflammation.Abbreviations
SES: Sirolimus-eluting stent; EPCs: Endothelial progenitor cells;
HCASES: Hyaluronan-chitosan (HC) and anti-CD34 antibody applied on a SES;
GS: Anti-CD34 antibody stent; SEM: Scanning electron microscopy;
ECs: Endothelial cells; LST: Late in-stent thrombosis.
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